Long-term clinical outcomes in HCV genotype 1-infected patients receiving ombitasvir/paritaprevir/ ritonavir and dasabuvir ± ribavirin: First interim safety and efficacy results from TOPAZ-I

Authors
Category Primary study
JournalHepatology
Year 2016
This article has no abstract
Epistemonikos ID: 52d724043f4e5db0f0bb07eae14a823d379136b2
First added on: Feb 08, 2025